Evidence map›Paper›PMID 24193170›Full record

ArticleClinical pharmacology and therapeutics2014

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

B C Carleton, C J Ross, A P Bhavsar, U Amstutz, K Pussegoda, H Visscher, J W Lee, B Brooks, S R Rassekh, M-P Dubé and 1 more

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Platinum-induced hearing loss after treatment for childhood cancer.The Cochrane database of systematic reviews · 2016
    Pooled it
  2. Article
  3. Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018
    Review
  4. Variants inClinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

B C Carleton1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
C J Ross1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
A P BhavsarChild and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
U Amstutz1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
K PussegodaChild and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
H VisscherChild and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada.
J W Lee1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
B BrooksAudiology and Speech Pathology Department, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
S R Rassekh1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
M-P DubéMontreal Heart Institute Research Centre and Université de Montreal, Montreal, Quebec, Canada.
M R Hayden1] Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsCatechol O-MethyltransferaseCisplatinFemaleHearing LossHumansMaleMethyltransferasesAntineoplastic AgentsCatechol O-MethyltransferaseCisplatinMethyltransferases

Identifiers

PMID24193170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.